? VDDRC PILOT AND FEASIBILITY PROGRAM The Pilot and Feasibility (P/F) Program is a vital, essential component of the Vanderbilt DDRC (VDDRC). It directly supports the overall goals of the VDDRC, which are to: 1) promote digestive diseases research in an integrative, collaborative, and multidisciplinary manner; 2) attract new investigators to the study of these disorders; 3) enhance the innovative research capabilities of members; and 4) promote the career development of junior investigators. Through the P/F Program, we have a strong track record of recruiting highly talented young investigators and established investigators that are new to digestive disease research, as well as established GI investigators testing exciting new ideas. In the past 10 years, we have supported 58 P/F recipients, with 27 of these in the past 5 years. Our number of grants and the amount of support is greatly enhanced by a commitment of $100,000 per year from VUMC, plus additional funding available from the Vanderbilt Institute for Clinical and Translational Research (VICTR, Vanderbilt CTSA). Over the past two grant award cycles (years 6-15), P/F recipients have garnered $47,707,648 in Direct Cost funding subsequent to their P/F awards, yielding a 30? fold return on investment of the NIH funds used for P/F awards. We have demonstrated major benefits to the career development of PIs that were supported as Type N (New Investigators) in the P/F program, including development of faculty as transformers of their research fields and growth into academic leadership positions. The P/F Program has been directed since 2010 by Keith T. Wilson, M.D., Thomas F. Frist Sr. Professor of Medicine, Cancer Biology, and Pathology, Microbiology and Immunology, and Associate Director of the VDDRC. The VDDRC provides an applicant-friendly environment in which annual P/F grant opportunities are widely circulated via the VDDRC website and email announcements, and potential candidates interact directly with the P/F Director to ensure that their projects meet the goals of the VDDRC, optimize use of VDDRC Cores, and meet NIH guidelines for rigor and reproducibility.
Our Specific Aims are: 1) To recruit talented New Investigators (Type N) without current or past independent NIH support to digestive disease research, in order to provide a foundation for career development and future independent funding; all successful Type N recipients benefit from enrollment in the VDDRC Academy of Investigators. 2) To recruit established investigators new to digestive disease research (Type EN), by supporting their studies of a digestive disease- related problem, with the goal of fostering collaborations and new directions that may lead to subsequent related publications, projects, and research grants in the field. 3) To support established investigators (Type E) in the digestive disease field in the pursuit of highly innovative, exciting new ideas, which is a significant departure from their previous work, and is likely to result in an important and fruitful new line of investigation. The overall goal is enhanced digestive disease-related research with exciting and transformative new ideas that can be catalyzed by P/F support and extensive interaction with Center members and activities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK058404-18
Application #
9710652
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2019-06-01
Budget End
2020-05-31
Support Year
18
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Sucre, Jennifer M S; Deutsch, Gail H; Jetter, Christopher S et al. (2018) A Shared Pattern of ?-Catenin Activation in Bronchopulmonary Dysplasia and Idiopathic Pulmonary Fibrosis. Am J Pathol 188:853-862
Saito-Diaz, Kenyi; Benchabane, Hassina; Tiwari, Ajit et al. (2018) APC Inhibits Ligand-Independent Wnt Signaling by the Clathrin Endocytic Pathway. Dev Cell 44:566-581.e8
Coppola, Jennifer J; Disney, Anita A (2018) Most calbindin-immunoreactive neurons, but few calretinin-immunoreactive neurons, express the m1 acetylcholine receptor in the middle temporal visual area of the macaque monkey. Brain Behav 8:e01071
Stier, Matthew T; Zhang, Jian; Goleniewska, Kasia et al. (2018) IL-33 promotes the egress of group 2 innate lymphoid cells from the bone marrow. J Exp Med 215:263-281
Schlegel, Cameron; Weis, Victoria G; Knowles, Byron C et al. (2018) Apical Membrane Alterations in Non-intestinal Organs in Microvillus Inclusion Disease. Dig Dis Sci 63:356-365
Zhu, Lin; Luu, Thao; Emfinger, Christopher H et al. (2018) CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet. Diabetes 67:2494-2506
Choi, Eunyoung; Lantz, Tyler L; Vlacich, Gregory et al. (2018) Lrig1+ gastric isthmal progenitor cells restore normal gastric lineage cells during damage recovery in adult mouse stomach. Gut 67:1595-1605
Heaster, Tiffany M; Walsh, Alex J; Zhao, Yue et al. (2018) Autofluorescence imaging identifies tumor cell-cycle status on a single-cell level. J Biophotonics 11:
Lu, Sichang; McGough, Madison A P; Shiels, Stefanie M et al. (2018) Settable polymer/ceramic composite bone grafts stabilize weight-bearing tibial plateau slot defects and integrate with host bone in an ovine model. Biomaterials 179:29-45
Petersen, Christine P; Meyer, Anne R; De Salvo, Carlo et al. (2018) A signalling cascade of IL-33 to IL-13 regulates metaplasia in the mouse stomach. Gut 67:805-817

Showing the most recent 10 out of 1365 publications